LEQ506
CAS No. 1204975-42-7
LEQ506 ( NVP-LEQ506 )
产品货号. M26278 CAS No. 1204975-42-7
LEQ506 是一种 Smo 抑制剂,对于 hSmo 和 mSmo 的 IC50 值分别为 2 nM 和 4 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥1340 | 有现货 |
|
| 10MG | ¥1910 | 有现货 |
|
| 25MG | ¥2883 | 有现货 |
|
| 50MG | ¥3878 | 有现货 |
|
| 100MG | ¥5049 | 有现货 |
|
| 200MG | ¥6804 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥1359 | 有现货 |
|
生物学信息
-
产品名称LEQ506
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述LEQ506 是一种 Smo 抑制剂,对于 hSmo 和 mSmo 的 IC50 值分别为 2 nM 和 4 nM。
-
产品描述LEQ506 is a Smo inhibitor with IC50s of 2 nM and 4 nM for hSmo and mSmo, respectively.(In Vitro):LEQ506 consistently decreases Gli1 mRNA by about 70 to 80%. LEQ506 shows a tendency to preferentially inhibit Gli1 rather than Ptch1 mRNA. LEQ506 (at 1%) is also an efficacious compound with an inhibition of 80 to 90% for Gli1 and 60 to 70% for Ptch1. LEQ506 inhibits Hedgehog signaling in a human cell line (HEPM) as measured by the amount of Gli mRNA with an IC50 ~6-fold lower than that of Compound 2.
-
体外实验LEQ506 is a second-generation inhibitor of smoothened (Smo) with IC50s of 2 and 4 nM in human and mouse, respectively. LEQ506 inhibits Hedgehog (Hh) signaling in a human cell line (HEPM) as measured by the amount of Gli mRNA with an IC50 ~6-fold lower than that of Compound 2. LEQ506 is an efficacious compound by consistently decreasing Gli1 mRNA by about 70 to 80%. LEQ506 shows a tendency to preferentially inhibit Gli1 rather than Ptch1 mRNA. LEQ506 (at 1%) is also an efficacious compound with an inhibition of 80 to 90% for Gli1 and of 60 to 70% for Ptch1.
-
体内实验——
-
同义词NVP-LEQ506
-
通路Wnt/Notch/Hedgehog
-
靶点Smoothened (Smo)
-
受体Cereblon
-
研究领域——
-
适应症——
化学信息
-
CAS Number1204975-42-7
-
分子量432.572
-
分子式C25H32N6O
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : ≥ 100 mg/mL (231.18 mM)
-
SMILESC[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1
021-51111890
购物车()
sales@molnova.cn

